Med. praxi. 2020;17(5):333-335

Gallstone disease, cholecystectomy indication

MUDr. Zuzana Adamová, Ph.D.
Chirurgické oddělení, Vsetínská nemocnice, a. s.

Gallbladder disease affects up to 20% of the European population and, if managed incorrectly, can lead to high rates of morbidity. The most common complications of gallstones include biliary colic, acute cholecystitis, common bile duct stones, and gallstone pancreatitis. Regular physical activity and an appropriate diet are the most important measures for the prevention of gallstone disease. Ultrasound is the initial imaging modality of choice. Biliary colic, acute cholecystitis and bigger gallbladder polyps are best treated with laparoscopic cholecystectomy, cholecystitis ideally in the first 24hours. Asymptomatic patients do not belong to the operation theatre.

Keywords: cholecystolithiasis, cholecystectomy, gallbladder polyps.

Published: January 5, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Adamová Z. Gallstone disease, cholecystectomy indication. Med. praxi. 2020;17(5):333-335.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. European Association for the Study of the Liver (EASL): EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. J Hepatol 2016; 65: 146-181. Go to original source... Go to PubMed...
    2. Attili AF, De Santis A, Capri R, et al. The natural history of gallstones: the GREPCO experience. The GREPCO Group. Hepatology 1995; 21: 655-660. Go to original source... Go to PubMed...
    3. Stender S, Nordestgaard BG, Tybjaerg-Hansen A. Elevated body mass index as a causal risk factor for symptomatic gallstone disease: a mendelian randomization study. Hepatology 2013; 58: 2133-2141. Go to original source... Go to PubMed...
    4. Weikert C, Weikert S, Schulze MB, et al. Presence of gallstones or kidney stones and risk of type 2 diabetes. AmJ Epidemiol 2010; 171: 447-454. Go to original source... Go to PubMed...
    5. Leitzmann MF, Rimm EB, Willett WC, et al. Recreational physical activity and the risk of cholecystectomy in women. N Engl J Med 1999; 341: 777-784. Go to original source... Go to PubMed...
    6. Leitzmann MF, Giovannucci EL, Rimm EB, et al. The relation of physical activity to risk for symptomatic gallstone disease in men. Ann Intern Med 1998; 128: 417-425. Go to original source... Go to PubMed...
    7. Storti KL, Brach JS, FitzGerald SJ, et al. Physicalactivity and decreased risk of clinical gallstone disease among postmenopausal women. Prev Med 2005; 41: 772-777. Go to original source... Go to PubMed...
    8. Simon JA, Hudes ES. Serum ascorbic acid and gallbladder disease prevalenceamong US adults: the Third National Health and Nutrition ExaminationSurvey (NHANES III). Arch Intern Med 2000; 160: 931-936. Go to original source... Go to PubMed...
    9. Misciagna G, Centonze S, Leoci C, et al. Diet, physical activity, and gallstones - A population-based, case-control study in southern Italy. Am J Clin Nutr 1999; 69: 120-126. Go to original source... Go to PubMed...
    10. Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. The effect of long-term intake of cis unsaturated fats on the risk for gallstone disease in men: a prospective cohort study. Ann Intern Med 2004; 141: 514-522. Go to original source... Go to PubMed...
    11. Stokes CS, Gluud LL, Casper M, Lammert F. Ursodeoxycholic acid and diets higher in fat prevent gallbladder stones during weight loss: a meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol 2014; 12: 1090-1100. Go to original source... Go to PubMed...
    12. Attanasio R, Mainolfi A, Grimaldi F, et al. Somatostatin analogs and gallstones: a retrospective survey on a large series of acromegalic patients. J Endocrinol Invest 2008; 31: 704-710. Go to original source... Go to PubMed...
    13. Gutt C, Schläfer S, Lammert F. The Treatment of Gallstone Disease. Dtsch Arztebl Int. 2020; 117(9): 148-158. doi: 10.3238/arztebl.2020.0148. Go to original source... Go to PubMed...
    14. Marek J. Farmakoterapie vnitřních nemocí. 4. zcela přepracované a doplněné vydání. Praha: Grada 2010: 208 s.
    15. Festi D, Reggiani ML, Attili AF, et al. Naturalhistory of gallstone disease: expectant management or active treatment? Results from a population-based cohort study. J Gastroenterol Hepatol 2010; 25: 719-724. Go to original source... Go to PubMed...
    16. Friedman GD, Raviola CA, Fireman B. Prognosis of gallstones with mild or no symptoms: 25 years of follow-up in a health maintenance organization. J Clin Epidemiol 1989; 42: 127-136. Go to original source... Go to PubMed...
    17. Ransohoff DF, Gracie WA, Wolfenson LB, Neuhauser D. Prophylactic holecystectomy or expectant management for silent gallstones. A decision analysis to assess survival. Ann Intern Med 1983; 99: 199-204. Go to original source... Go to PubMed...
    18. Ashur H, Siegal B, Oland Y, Adam YG. Calcified gallbladder (porcelain gallbladder). Arch Surg 1978; 113: 594-596. Go to original source... Go to PubMed...
    19. Wiles R, Varadpande M, Muly S, Webb J. Growth rate and malignant potential of small gallbladder polyps - systematic review of evidence. Surgeon 2014; 12: 221-226. Go to original source... Go to PubMed...
    20. Wiles R, Thoeni FR, Barbu ST, et al. Management and follow-up of gallbladder polyps. Eur Radiol 2017; 27: 3856-3866. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.